title: Meeting the current and future challenges of oncology drug development.
abstract: This breakout session highlighted four distinct perspectives from leading individuals within patient advocacy, industry, an appraisal committee and physicians on the future and challenges faced by targeted therapy in HTA evaluation. Bringing together leaders from key stakeholders in the process, it gave participants the opportunity to examine how the same HTA evaluation process is interpreted from multiple perspectives. The presentation of an industry supported "Six Nation Public Opinion Survey of Cancer Knowledge and Attitudes" provided detailed insight into how the general public, patients and caregivers view cancer alongside various available and possible future therapies. An interactive 'perspectives activity' session provided all participants with an opportunity to think through and discuss the HTA process, and its challenges, from the four distinct positions involved. We declare that we have no conflicts of interest.
authors.affiliation: Eli Lilly and Company, Lilly UK, Surrey, UK.
authors.forename: Moira
authors.initials: M
authors.lastname: Howie
authors.affiliation: International Brain Tumour Alliance, UK.
authors.forename: Kathy
authors.initials: K
authors.lastname: Oliver
authors.affiliation: Scottish Medicines Consortium, UK.
authors.forename: Angela
authors.initials: A
authors.lastname: Timoney
authors.affiliation: European Institute of Oncology, Via G.Ripamonti, 435-20141 Milan, Italy.
authors.forename: Gordon
authors.initials: G
authors.lastname: McVie